3-methoxy-4-(methylsulfanyl)phenol | 19555-09-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-methoxy-4-(methylsulfanyl)phenol
• 英文别名: 3-methoxy-4-(methylthio)phenol；4-methylthio-3-methoxyphenol；3-Methoxy4-(methylsulfanyl)phenol；1-Hydroxy-3-methoxy-4-methylthio-benzol；3-Methoxy-4-methylmercapto-phenol；3-methoxy-4-methylsulfanylphenol
• CAS: 19555-09-0
• 化学式: C₈H₁₀O₂S
• 分子量: 170.232
• InChiKey: CMEBWWOWPGWUBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methoxy-4-(methylsulfanyl)phenol 在 盐酸 、 potassium nitrososulfonate 作用下， 以 甲醇 为溶剂， 生成 2-Methoxy-5-methylthio-p-benzochinon
  参考文献：
  名称：

  Ukai,S.; Hirose,K., Chemical and pharmaceutical bulletin, 1968, vol. 16, # 2, p. 202 - 210

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(allyloxy)-2-methoxy-1-(methylsulfanyl) benzene 在 四(三苯基膦)钯 sodium tetrahydroborate 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 14.0h， 生成 3-methoxy-4-(methylsulfanyl)phenol
  参考文献：
  名称：

  [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS
  [FR] DERIVES DE NICOTINAMIDE AGISSANT COMME INHIBITEURS DE PDE4

  摘要：

  这项发明涉及式(I)的烟酰胺衍生物，以及含有该类衍生物的药物组合物，以及将这些衍生物用作PDE4抑制剂的用途，其中R7连接到苯环的3-或4-位，并且为S(O)pR8，R8为(C1-C4)烷基，可选择地被(C3-C6)环烷基取代；m为0或1；L为(C3-C8)非芳香环；其余变量如索权中所定义。

  公开号：

  WO2005009966A1

文献信息

• Phenyl heterocyclyl ethers
  申请人：——

  公开号：US20030207857A1

  公开（公告）日：2003-11-06

  The invention relates to compounds of formula I 1

  该发明涉及公式I1的化合物。
• Diphenyl ether compounds useful in therapy
  申请人：——

  公开号：US20020052395A1

  公开（公告）日：2002-05-02

  A compound of general formula (I), or pharmaceutically acceptable salts, solvates or polymorphs thereof; wherein; R 1 and R 2 , which may be the same or different, are hydrogen, C 1 -C 6 alkyl, (CH 2 )m(C 3 -C 6 cycloalkyl) wherein m =0, 1, 2 or 3, or R 1 and R 2 together with the nitrogen to which they are attached form an azetidine ring; each R 3 is independently CF 3 , OCF 3 , C 1-4 alkylthio or C 1 -C 4 alkoxy; n is 1, 2 or 3; and R 4 and R 5 , which may be the same or different, are: A-X, wherein A =—CH=CH— or —(CH 2 )p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR 6 R 7 ,SO 2 NR 6 R 7 , SO 2 NHC(=O)R 6 , OH, C 1-4 alkoxy, NR 8 SO 2 R 9 , NO 2 , NR 6 R 11 , CN, CO 2 R 10 , CHO, SR 10 , S(O)R 9 or SO 2 R 10 R 6 , R 7 , R and R 10 which may be the same or different, are hydrogen or C 1-6 alkyl optionally substituted independently by one or more R 12 ; R 9 is C 1-6 alkyl optionally substituted independently by one or more R 12 ; R 11 is hydrogen, C 1-6 alkyl optionally substituted independently by one or more R 12 , C(O)R 6 , CO 2 R 9 , C(O)NHR 6 or SO 2 NR 6 R 7 ; R 12 is F, OH, CO 2 H, C 3-6 cycloalkyl, NH 2 , CONH 2 , C 1-6 alkoxy, C 1-6 alkoxycarbonyl or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O optionally substituted independently by one or more R 13 ; or R 6 and R 7 , together with the nitrogen to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring optionally substituted independently by one or more R 13 ; or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, optionally substituted independently by one or more R 13 ; wherein R 13 is hydroxy, C 1 -C 4 alkoxy, F, C 1 -C 6 alkyl, haloalkyl, haloalkoxy, —NH 2 , —NH(C 1 -C 6 alkyl) or —N(C 1 -C 6 alkyl) 2 ; wherein when R 1 and R 2 are methyl, R 4 and R 5 are hydrogen and n is 1, R 3 is not a —SMe group para to the ether linkage linking rings A and B. 1

  通用式（I）的化合物，或其药学上可接受的盐、溶剂化合物或多晶型；其中；R1和R2，可能相同或不同，为氢、C1-C6烷基、（CH2）m（C3-C6环烷基）其中m=0、1、2或3，或者R1和R2与它们连接的氮一起形成氮杂环丙烷环；每个R3独立地为CF3、OCF3、C1-4烷基硫或C1-C4烷氧基；n为1、2或3；以及R4和R5，可能相同或不同，为：A-X，其中A=-CH=CH-或-(CH2)p-其中p为0、1或2；X为氢、F、Cl、Br、I、CONR6R7、SO2NR6R7、SO2NHC(=O)R6、OH、C1-4烷氧基、NR8SO2R9、NO2、NR6R11、CN、CO2R10、CHO、SR10、S(O)R9或SO2R10R6，R7，R和R10可能相同或不同，为氢或C1-6烷基，可选地独立地被一个或多个R12取代；R9为C1-6烷基，可选地独立地被一个或多个R12取代；R11为氢、C1-6烷基，可选地独立地被一个或多个R12取代，C(O)R6，CO2R9，C(O)NHR6或SO2NR6R7；R12为F、OH、CO2H、C3-6环烷基、NH2、CONH2、C1-6烷氧基、C1-6烷氧羰基或含有1、2或3个异原子（N、S和O）的5-或6元杂环，可选地独立地被一个或多个R13取代；或R6和R7，与它们连接的氮一起，形成一个可选地被一个或多个R13取代的4、5或6元杂环；或含有1、2或3个异原子（N、S和O）的5-或6元杂环，可选地独立地被一个或多个R13取代；其中R13为羟基、C1-C4烷氧基、F、C1-C6烷基、卤代烷基、卤代烷氧基、-NH2、-NH(C1-C6烷基)或-N(C1-C6烷基)2；当R1和R2为甲基时，R4和R5为氢，n为1，R3不是SMe基固定在连接环A和B的醚键旁。
• [EN] PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS<br/>[FR] DERIVES DE PHENYLE HETEROCYCLYLE ETHER UTILISES COMME INHIBITEURS DU RECAPTAGE DE LA SEROTONINE
  申请人：PFIZER LTD

  公开号：WO2002083643A1

  公开（公告）日：2002-10-24

  The invention relates to compounds of the formula (I) which exhibit activity as selective serotonin re-uptake inhibitors.

  本发明涉及公式（I）的化合物，其表现出作为选择性血清素再摄取抑制剂的活性。
• Nicotinamide derivatives useful as PDE4 inhibitors
  申请人：Bailey Simon

  公开号：US20050032838A1

  公开（公告）日：2005-02-10

  This invention relates to nicotinamide derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing, and the uses of such derivatives: wherein R 1 is selected from the group consisting of hydrogen, methyl or halo; R 7 is attached to the 3- or 4-position of the phenyl ring and is S(O) p R 8 , R 8 is (C 1 -C 4 )alkyl optionally substituted by (C 3 -C 6 )cycloalkyl; p is 0, 1 or 2; R 6 is selected from the group consisting of hydrogen, halo, (C 1 -C 3 )alkyl and (C 1 -C 3 )alkoxy; m is 0 or 1; L is a (C 3 -C 8 )carbocyclic non-aromatic ring; R 2 is hydrogen, hydroxy, (C 1 -C 3 )alkoxy, (C 1 -C 3 )alkyl (optionally substituted by hydroxy or by (C 1 -C 3 )alkoxy), CO 2 R 9 , NR 10 R 11 or CONR 10 R 11 ; R 3 is hydrogen or (C 1 -C 3 )alkyl; R 9 is hydrogen or (C 1 -C 3 )alkyl; R 10 and R 11 are each independently hydrogen, or, are selected from the group consisting of: (C 1 -C 6 )alkyl optionally substituted by phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; (C 3 -C 8 )cycloalkyl; CO((C 1 -C 6 )alkyl) optionally substituted by hydroxy, halo, (C 3 -C 8 )cycloalkyl, (C 1 -C 3 )alkoxy, phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; CO(R 12 ), wherein R 12 is (C 3 -C 8 )cycloalkyl optionally substituted by (C 1 -C 3 )alkyl or R 12 is phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; and CO 2 (C 1 -C 3 )alkyl); or R 10 and R 11 are taken together with the N atom to which they are attached to form a 5- or 6-membered lactam.

  本发明涉及化合物(I)的烟酰胺衍生物，以及制备这些衍生物的中间体的制备方法，含有这些衍生物的制药组合物，以及这些衍生物的用途：其中R1选自氢、甲基或卤素的群；R7附加到苯环的3-或4-位上，为S（O）pR8，R8为（C1-C4）烷基，可选地被（C3-C6）环烷基取代，p为0、1或2；R6选自氢、卤素、（C1-C3）烷基和（C1-C3）烷氧基的群；m为0或1；L为（C3-C8）非芳香环烷基；R2为氢、羟基、（C1-C3）烷氧基、（C1-C3）烷基（可选地被羟基或（C1-C3）烷氧基取代）、CO2R9、NR10R11或CONR10R11的群；R3为氢或（C1-C3）烷基；R9为氢或（C1-C3）烷基；R10和R11各自独立地选自以下群：（C1-C6）烷基，可选地被苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环取代，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；（C3-C8）环烷基；CO（（C1-C6）烷基），可选地被羟基、卤素、（C3-C8）环烷基、（C1-C3）烷氧基、苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环取代，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；CO（R12），其中R12为（C3-C8）环烷基，可选地被（C1-C3）烷基取代，或R12为苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；以及R10和R11一起与它们所附着的N原子形成5-或6-成员内酰胺。
• Direct lithiation of alkoxyphenols: metalation versus demethylation. An experimental and theoretical (MNDO) study
  作者：Jeroni Morey、Antoni Costa、Pere M. Deya、Guillem Suner、Jose M. Saa

  DOI：10.1021/jo00299a038

  日期：1990.6